REIMUND SERAFICA: Open Payments
NPI 1245823863 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,701 in 63 payments from 9 companies in 2025. Trend: 2023 $25 · 2024 $1,653 · 2025 $1,701
Food & beverage: $1,701
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $606 |
| ABBVIE INC. | 16 | $597 |
| Vanda Pharmaceuticals Inc. | 14 | $218 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $53 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $32 |
| Alkermes, Inc. | 1 | $16 |
Products named: REXULTI, VRAYLAR, FANAPT, AUSTEDO XR, Qelbree, CAPLYTA, Jornay PM, ARISTADA.
Industry payments across NV — which companies pay providers there.
